AbbVie Inc. (ABBV) 의 후행 P/E는 88.9, 선행 P/E 14.5. 후행 이익수익률은 1.12%, 선행 이익수익률 6.89%. PEG 0.03 (Peter Lynch 저평가 ≤1.0).
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 61/100 3/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | 17.1 | 1.07 | 21.91 | 3.96 | 3.66% |
| 2017 | 29.1 | -3.12 | 30.28 | 5.47 | 2.66% |
| 2018 | 25.0 | 2.18 | -16.82 | 4.34 | 3.93% |
| 2019 | 16.6 | 0.38 | -16.05 | 3.94 | 4.85% |
| 2020 | 38.7 | -0.80 | 13.66 | 3.90 | 4.32% |
| 2021 | 20.8 | 0.15 | 15.55 | 4.26 | 3.86% |
| 2022 | 24.2 | 9.22 | 16.59 | 4.93 | 3.51% |
| 2023 | 56.3 | -0.96 | 26.45 | 5.04 | 3.85% |
| 2024 | 73.5 | -6.08 | 94.54 | 5.58 | 3.51% |
| 2025 | 96.8 | -116.18 | -125.12 | 6.69 | 2.85% |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $3.63 | $25.64B | $5.95B | 23.2% |
| 2017 | $3.30 | $28.22B | $5.31B | 18.8% |
| 2018 | $3.68 | $32.75B | $5.69B | 17.4% |
| 2019 | $5.28 | $33.27B | $7.88B | 23.7% |
| 2020 | $2.72 | $45.8B | $4.62B | 10.1% |
| 2021 | $6.45 | $56.2B | $11.54B | 20.5% |
| 2022 | $6.63 | $58.05B | $11.84B | 20.4% |
| 2023 | $2.72 | $54.32B | $4.86B | 9% |
| 2024 | $2.39 | $56.33B | $4.28B | 7.6% |
| 2025 | $2.36 | $61.16B | $4.23B | 6.9% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $14.57 | $14.22 – $15.29 | $67.15B | $66.64B – $67.69B | 19 |
| 2027 | $16.19 | $15.20 – $17.48 | $72.31B | $70.33B – $73.61B | 18 |
| 2028 | $17.87 | $13.13 – $21.13 | $77.59B | $77.51B – $77.67B | 12 |
| 2029 | $19.55 | $19.08 – $19.89 | $81.74B | $80.23B – $82.84B | 10 |
| 2030 | $20.05 | $19.57 – $20.41 | $83.44B | $81.9B – $84.57B | 5 |
